The boom in weight loss products has long since spread to the stock markets. While the shares of pharmaceutical companies Novo Nordisk and Eli Lilly are benefiting from the high demand, other industry giants are also looking to follow. However, experts are also warning of possible side effects of the drugs, which were originally developed to treat diabetes.
Article on tag "Novo Nordisk"
Money tip: Are biotechnology stocks at the outset of a new upswing?
Biotechnology stocks have been back in the spotlight since the beginning of the year. Successes in research and market approvals for new drugs could provide fresh impetus. Is the sector worth a look now?
Miracle drug semaglutide: slim by injection
Originally, the Danish company Novo Nordisk wanted to develop Semaglutid as a drug for diabetes 2 patients. However, the appetite-reducing effect of the drug soon became apparent, making semaglutide a miracle cure for obesity. While Novo Nordisk’s share price has risen significantly since then, possible side effects of the drug are now also being examined.